Jeffrey M Dodd-O1, Sudipto Ganguly2, Ante Vulic2, Angela Panoskaltsis-Mortari3, John F McDyer4, Leo Luznik2. 1. Department of Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Division of Hematologic Malignances, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. 3. University of Minnesota Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN. 4. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213.
Abstract
BACKGROUND: Despite broad and intense conventional immunosuppression, long-term survival after lung transplantation lags behind that for other solid organ transplants, primarily because of allograft rejection. Therefore, new strategies to promote lung allograft acceptance are urgently needed. The purpose of the present study was to induce allograft tolerance with a protocol compatible with deceased donor organ utilization. METHODS: Using the major histocompatibility complex-mismatched mouse orthotopic lung transplant model, we investigated a conditioning regimen consisting of pretransplant T cell depletion, low-dose total body irradiation and posttransplant (donor) bone marrow, and splenocyte infusion followed by posttransplantation cyclophosphamide. RESULTS: Our results show that C57BL/6 recipients of BALB/c lung allografts undergoing this complete short-duration nonmyeloablative conditioning regimen had durable lung allograft acceptance. Mice that lacked 1 or more components of this regimen exhibited significant graft loss. Mechanistically, animals with lung allograft acceptance had established higher levels of donor chimerism, lymphocyte responses which were attenuated to donor antigens but maintained to third-party antigens, and clonal deletion of donor-reactive host Vβ T cells. Frequencies of Foxp3 T regulatory cells were comparable in both surviving and rejected allografts implying that their perturbation was not a dominant cell-regulatory mechanism. Donor chimerism was indispensable for sustained tolerance, as evidenced by acute rejection of allografts in established chimeric recipients of posttransplantation cyclophosphamide after a chimerism-ablating secondary recipient lymphocyte infusion. CONCLUSIONS: Together, these data provide proof-of-concept for establishing lung allograft tolerance with tandem donor bone marrow transplantation using a short-duration nonmyeloablative conditioning regimen and posttransplant cyclophosphamide.
BACKGROUND: Despite broad and intense conventional immunosuppression, long-term survival after lung transplantation lags behind that for other solid organ transplants, primarily because of allograft rejection. Therefore, new strategies to promote lung allograft acceptance are urgently needed. The purpose of the present study was to induce allograft tolerance with a protocol compatible with deceased donor organ utilization. METHODS: Using the major histocompatibility complex-mismatched mouse orthotopic lung transplant model, we investigated a conditioning regimen consisting of pretransplant T cell depletion, low-dose total body irradiation and posttransplant (donor) bone marrow, and splenocyte infusion followed by posttransplantation cyclophosphamide. RESULTS: Our results show that C57BL/6 recipients of BALB/c lung allografts undergoing this complete short-duration nonmyeloablative conditioning regimen had durable lung allograft acceptance. Mice that lacked 1 or more components of this regimen exhibited significant graft loss. Mechanistically, animals with lung allograft acceptance had established higher levels of donor chimerism, lymphocyte responses which were attenuated to donor antigens but maintained to third-party antigens, and clonal deletion of donor-reactive host Vβ T cells. Frequencies of Foxp3 T regulatory cells were comparable in both surviving and rejected allografts implying that their perturbation was not a dominant cell-regulatory mechanism. Donor chimerism was indispensable for sustained tolerance, as evidenced by acute rejection of allografts in established chimeric recipients of posttransplantation cyclophosphamide after a chimerism-ablating secondary recipient lymphocyte infusion. CONCLUSIONS: Together, these data provide proof-of-concept for establishing lung allograft tolerance with tandem donor bone marrow transplantation using a short-duration nonmyeloablative conditioning regimen and posttransplant cyclophosphamide.
Authors: Joseph Leventhal; Michael Abecassis; Joshua Miller; Lorenzo Gallon; Kadiyala Ravindra; David J Tollerud; Bradley King; Mary Jane Elliott; Geoffrey Herzig; Roger Herzig; Suzanne T Ildstad Journal: Sci Transl Med Date: 2012-03-07 Impact factor: 17.956
Authors: C D Fitzhugh; R P Weitzel; M M Hsieh; O A Phang; C Madison; L Luznik; J D Powell; J F Tisdale Journal: Bone Marrow Transplant Date: 2013-04-22 Impact factor: 5.483
Authors: John D Scandling; Stephan Busque; Sussan Dejbakhsh-Jones; Claudia Benike; Maria T Millan; Judith A Shizuru; Richard T Hoppe; Robert Lowsky; Edgar G Engleman; Samuel Strober Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: Scott S Graves; David W Mathes; George E Georges; Christian S Kuhr; Jeff Chang; Tiffany M Butts; Rainer Storb Journal: Transplantation Date: 2012-09-27 Impact factor: 4.939
Authors: M Okazaki; A S Krupnick; C G Kornfeld; J M Lai; J H Ritter; S B Richardson; H J Huang; N A Das; G A Patterson; A E Gelman; D Kreisel Journal: Am J Transplant Date: 2007-06 Impact factor: 8.086
Authors: R J Jones; J P Barber; M S Vala; M I Collector; S H Kaufmann; S M Ludeman; O M Colvin; J Hilton Journal: Blood Date: 1995-05-15 Impact factor: 22.113
Authors: Katharina Jansson; Karla Dreckmann; Wiebke Sommer; Murat Avsar; Jawad Salman; Thierry Siemeni; Ann-Kathrin Knöfel; Linda Pauksch; Jens Gottlieb; Jörg Frühauf; Martin Werner; Danny Jonigk; Martin Strüber; Axel Haverich; Gregor Warnecke Journal: Transplant Direct Date: 2017-06-06